A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety: Incidence of adverse events
approximately 1 year
No
Daniel Maslyar, M.D.
Study Director
Genentech
United States: Food and Drug Administration
DMO4993g
NCT01469793
November 2011
August 2015
Name | Location |
---|---|
Alexandria, Minnesota 56308 | |
Phoenix, Arizona 85012 | |
Miami, Florida 33176 | |
Denver, Colorado |